Claritas Genomics announces start of Claritas Clinical Exome, novel diagnostic test Claritas Genomics, Inc. Patients with rare disease seek a analysis for 8-12 years typically, receiving 3-5 separate tests at a higher cost. The sequential testing approach is now able to be replaced by a single test daily basis . The Claritas strategy takes advantage of an innovative dual-capture, dual-platform technique that immediately confirms a lot more than 90 percent of all genetic variants in the exome, facilitating rapid evaluation, interpretation, and return of clinically-relevant outcomes.
‘Following an estimated six-month treatment period, in April 2011 the last subject enrolled should complete treatment. We have a much top-line study results in early Q3 2011, which will be followed by an FDA submission in Q4 2011.’ Mr. Larry Andrews, President and CEO of Cipher, added: ‘Isotretinoin remains the most efficient treatment for severe, nodular acne. We believe our product’s unique attributes, specially the more consistent absorption profile, would provide a significant advancement in the treating this disease and offer dermatologists a fantastic alternative. We look forward to completing this final medical research as Cipher and its own partner, Ranbaxy Pharmaceuticals, function toward commercialization of the product in the $700 million U.S. Isotretinoin market.’.. Cipher completes enrolment in CIP-ISOTRETINOIN Phase III research for severe, nodular acne Cipher Pharmaceuticals Inc.